These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8234324)

  • 1. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
    Wilson DK; Tarle I; Petrash JM; Quiocho FA
    Proc Natl Acad Sci U S A; 1993 Nov; 90(21):9847-51. PubMed ID: 8234324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
    Nakano T; Petrash JM
    Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural studies of aldo-keto reductase inhibition.
    Wilson DK; Nakano T; Petrash JM; Quiocho FA
    Adv Exp Med Biol; 1997; 414():435-42. PubMed ID: 9059648
    [No Abstract]   [Full Text] [Related]  

  • 4. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.
    Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA
    Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
    Singh SB; Malamas MS; Hohman TC; Nilakantan R; Carper DA; Kitchen D
    J Med Chem; 2000 Mar; 43(6):1062-70. PubMed ID: 10737739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
    Mylari BL; Larson ER; Beyer TA; Zembrowski WJ; Aldinger CE; Dee MF; Siegel TW; Singleton DH
    J Med Chem; 1991 Jan; 34(1):108-22. PubMed ID: 1899452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
    El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
    Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of human aldehyde reductase: characterization of the active site pocket.
    Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
    Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat.
    Kinoshita T; Miyake H; Fujii T; Takakura S; Goto T
    Acta Crystallogr D Biol Crystallogr; 2002 Apr; 58(Pt 4):622-6. PubMed ID: 11914486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications.
    Wilson DK; Bohren KM; Gabbay KH; Quiocho FA
    Science; 1992 Jul; 257(5066):81-4. PubMed ID: 1621098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
    Fresneau P; Cussac M; Morand JM; Szymonski B; Tranqui D; Leclerc G
    J Med Chem; 1998 Nov; 41(24):4706-15. PubMed ID: 9822541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site.
    El-Kabbani O; Rogniaux H; Barth P; Chung RP; Fletcher EV; Van Dorsselaer A; Podjarny A
    Proteins; 2000 Nov; 41(3):407-14. PubMed ID: 11025551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of porcine aldehyde reductase holoenzyme.
    el-Kabbani O; Judge K; Ginell SL; Myles DA; DeLucas LJ; Flynn TG
    Nat Struct Biol; 1995 Aug; 2(8):687-92. PubMed ID: 7552731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-induced fit affects binding modes and provokes changes in crystal packing of aldose reductase.
    Koch C; Heine A; Klebe G
    Biochim Biophys Acta; 2011 Sep; 1810(9):879-87. PubMed ID: 21684320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
    Urzhumtsev A; Tête-Favier F; Mitschler A; Barbanton J; Barth P; Urzhumtseva L; Biellmann JF; Podjarny A; Moras D
    Structure; 1997 May; 5(5):601-12. PubMed ID: 9195881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
    El-Kabbani O; Old SE; Ginell SL; Carper DA
    Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The crystal structure of the aldose reductase.NADPH binary complex.
    Borhani DW; Harter TM; Petrash JM
    J Biol Chem; 1992 Dec; 267(34):24841-7. PubMed ID: 1447221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of CHO reductase, a member of the aldo-keto reductase superfamily.
    Ye Q; Hyndman D; Li X; Flynn TG; Jia Z
    Proteins; 2000 Jan; 38(1):41-8. PubMed ID: 10651037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1.7 A structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor.
    Wilson DK; Nakano T; Petrash JM; Quiocho FA
    Biochemistry; 1995 Nov; 34(44):14323-30. PubMed ID: 7578036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
    Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH
    Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.